September 2023

Contents

Editorial

• HTB September/October 2023

• Non-technical summary of articles in HTB September/October 2023

Early access

• Early phase 1 HIV vaccine study launched in the US and South Africa

• High rates of re-suppression with dolutegravir in the ADVANCE study

• EU approves cabotegravir as injectable PrEP

• Altered kidney function associated with alcohol and cannabis use by women living with HIV

• Bictegravir use in pregnancy: more data needed

Conference reports

• 12th IAS Conference on HIV Science (IAS 2023): further reports

• IAS 2023: Update to navigating the programme and online access

• IAS 2023: Metabolic and weight changes using GLP-1 agonists in people living with HIV: need for more data

• IAS 2023: CHAPAS-4 supports better second-line options for children

• IAS 2023: Rapporteur summary track A – basic science

• IAS 2023: Rapporteur summary track C – prevention

• IAS 2023: Rapporteur summary track D – social and behavioural science

Pathogenesis

• Defective HIV proviral particles linked to persistent inflammation and immune activation despite effective ART

• Cannabis does not reduce T cells in people living with HIV

mpox (monkeypox)

• Tecovirimat resistance in a person with advanced HIV and delayed ART

Coinfections and complications

• Timing of ART with cryptococcus: Europe and the US cohort data challenged by African RCT data and editorial comment

• Peripheral inflammation linked to structural brain changes and reduced blood flow despite suppressive ART

Future meetings

• Future meetings and webinars 2023/24

PDFs

• HTB: no. 9/10 (Sept/Oct 2023) PDF download